Get the Stockscreener App
32.26
0.59%
0.12
Viking Therapeutics Inc stock is traded at $32.26, with a volume of 2.90M.
It is up +0.59% in the last 24 hours and down -16.13% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$32.14
Open:
$31.88
24h Volume:
2.90M
Relative Volume:
0.78
Market Cap:
$3.65B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-34.69
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-8.47%
1M Performance:
-16.13%
6M Performance:
+14.69%
1Y Performance:
-23.98%
1-Day Range:
$31.56
$33.28
1-Week Range:
$31.56
$36.17
52-Week Range:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.30 | 3.63B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.00 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
775.08 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.94 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.86 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Looking Into Viking Therapeutics Inc's Recent Short Interest - Benzinga
Insider Sales and Market Competition Weigh on Viking Therapeutics Shares - AD HOC NEWS
Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing - marketscreener.com
Leadership Stock Sales Cast Shadow Over Viking Therapeutics’ Prospects - AD HOC NEWS
What drives Viking Therapeutics Inc 1VT stock pricePrice Action Analysis & Low Risk Wealth Building - earlytimes.in
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Insider Sell Alert: Matthew Foehr Sells 16,000 Shares of Viking Therapeutics Inc (VKTX) - GuruFocus
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms - Stocktwits
Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock - MarketBeat
Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics CEO Lian sells $7.69m in shares By Investing.com - Investing.com Nigeria
Viking therapeutics CFO Zante sells $1.89m in shares By Investing.com - Investing.com India
Viking Therapeutics CEO Lian sells $7.69m in shares - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock By Investing.com - Investing.com UK
Viking Therapeutics director Foehr sells $561,694 in shares - Investing.com
Viking Therapeutics director Foehr sells $561,694 in shares By Investing.com - Investing.com UK
A Look At Viking Therapeutics (VKTX) Valuation As Long Term Gains Contrast Recent Losses - simplywall.st
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Trading Down 6.1%What's Next? - MarketBeat
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing - ts2.tech
$VKTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Viking Therapeutics 2026: How Brian Lian Built a $4B Metabolic Fortress - CEO Today
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company - Forbes
Viking Therapeutics Shares Consolidate as Investors Await Clinical Catalyst - AD HOC NEWS
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: A Tale of Clinical Momentum and Financial Strain - AD HOC NEWS
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III - sharewise.com
Viking Therapeutics Accelerates Toward Pivotal Obesity Drug Data - AD HOC NEWS
Viking Therapeutics, Inc. $VKTX Shares Sold by Voya Investment Management LLC - MarketBeat
Viking Therapeutics Achieves Key Clinical Milestone Ahead of Schedule - AD HOC NEWS
Viking Therapeutics: A Wide-Open Oral GLP-1 Market (NASDAQ:VKTX) - Seeking Alpha
2 beaten-down stocks that could bounce back in 2026 - MSN
2 Beaten-Down Stocks That Could Bounce Back in 2026 - Finviz
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - ADVFN
Viking Therapeutics: A High-Stakes Investment at a Critical Juncture - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Viking Therapeutics Shares Face Mounting Pressure - AD HOC NEWS
Insider Selling and Clinical Progress Shape Viking Therapeutics’ Stock Trajectory - AD HOC NEWS
Harbor Capital Advisors Inc. Trims Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Investors Eye Pivotal Phase 3 Catalyst - AD HOC NEWS
Viking Therapeutics' Swing Trade Potential EmergesCompetition/Dilution Risks Remain (NASDAQ:VKTX) - Seeking Alpha
Price Action: Is Viking Therapeutics Inc. stock a good choice for value investorsMarket Volume Report & Real-Time Sentiment Analysis - moha.gov.vn
Viking Therapeutics, Inc. (VKTX) beats stock market upswing: What investors need to know - MSN
Market Moves: Is Viking Therapeutics Inc. stock a good choice for value investorsJuly 2025 Market Mood & Growth Focused Entry Reports - moha.gov.vn
Could Viking Therapeutics Become the Next Eli Lilly? - AOL.com
Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Sahm
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):